Ciobanu Liviu C, Boivin Roch P, Luu-The Van, Poirier Donald
Medicinal Chemistry Division, Oncology and Molecular Endocrinology Research Center, Centre Hospitalier Universitaire de Quebec (CHUQ-Pavillon CHUL) 2705 Boulevard Laurier and Laval University, Québec, Qc., G1V 4G2, Canada.
J Enzyme Inhib Med Chem. 2003 Feb;18(1):15-26. doi: 10.1080/1475636031000069282.
A series of C19 and C21 steroids bearing one or two inhibiting groups (3beta-sulfamate and 17alpha- or 20(S)-t-butylbenzyl or benzyl) were synthesized and tested for inhibition of steroid sulfatase activity. When only a sulfamate group was added to dehydroepiandrosterone, androst-5-ene-3beta,17beta-diol, pregnenolone and 20-hydroxy-pregnenolone, no significant inhibition of steroid sulfatase occurred at concentrations of 0.3 and 3 microM. With only a t-butylbenzyl or a benzyl group, a stronger steroid sulfatase inhibition was obtained in the androst-5-ene than in the pregn-5-ene series. Comparative results from the screening tests and the IC50 values have shown that the effect of a sulfamate moiety as a second inhibiting group can be combined to the t-butylbenzyl or benzyl effect in the C19 and C21 steroid series. The 3beta-sulfamoyloxy-17alpha-t-butylbenzyl-5-androsten-17beta-ol (10) was thus found to be the most active compound with IC50 values of 46 +/- 8 and 14 +/- 1 nM, respectively for the transformations of E1S to E1 and DHEAS to DHEA. The IC50 values of compound 10 are similar to that of 17alpha-t-butylbenzyl-estradiol, which was previously reported by our group as a good steroid sulfatase reversible inhibitor, but remains higher than that of the potent inactivators estrone-3-O-sulfamate (EMATE) and 17alpha-t-butylbenzyl-EMATE. However, contrary to these two latter inhibitors, compound 10 did not induce any proliferative effect on estrogen-sensitive ZR-75-1 cells nor on androgen-sensitive Shionogi cells at concentrations tested, suggesting that this steroid sulfatase inhibitor is non estrogenic and non androgenic.
合成了一系列带有一个或两个抑制基团(3β-氨基磺酸酯和17α-或20(S)-叔丁基苄基或苄基)的C19和C21甾体,并测试了它们对甾体硫酸酯酶活性的抑制作用。当仅将一个氨基磺酸酯基团添加到脱氢表雄酮、雄甾-5-烯-3β,17β-二醇、孕烯醇酮和20-羟基孕烯醇酮时,在0.3和3 microM浓度下未观察到对甾体硫酸酯酶的显著抑制作用。仅带有叔丁基苄基或苄基时,在雄甾-5-烯系列中比在孕甾-5-烯系列中获得了更强的甾体硫酸酯酶抑制作用。筛选试验和IC50值的比较结果表明,氨基磺酸酯部分作为第二个抑制基团的作用可以与C19和C21甾体系列中的叔丁基苄基或苄基作用相结合。因此,发现3β-氨磺酰氧基-17α-叔丁基苄基-5-雄甾烯-17β-醇(10)是最具活性的化合物,对于E1S向E1以及DHEAS向DHEA的转化,其IC50值分别为46±8和14±1 nM。化合物10的IC50值与17α-叔丁基苄基雌二醇相似,我们小组之前曾报道该化合物是一种良好的甾体硫酸酯酶可逆抑制剂,但仍高于强效灭活剂雌酮-3-O-氨基磺酸酯(EMATE)和17α-叔丁基苄基-EMATE。然而,与后两种抑制剂不同,在测试浓度下,化合物10对雌激素敏感的ZR-75-1细胞和雄激素敏感的Shionogi细胞均未诱导任何增殖作用,这表明该甾体硫酸酯酶抑制剂无雌激素活性和雄激素活性。